Chronic Myelogenous Leukemia
Merck, Vertex initiate trial of Aurora kinase inhibitor in treatment-resistant leukemias
Published in Gene Therapy Weekly, January 25th, 2007
The trial will be conducted in patients with treatment resistant chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphocytic leukemia (Ph+ ALL) containing the T315I BCR-ABL mutation. In connection with the start of dosing in the trial, which is designed to support registration of MK-0457 in the United States and other countries, Vertex earned a $25 million milestone payment from Merck.
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2007-01-25)
More Articles from Gene Therapy Weekly
- Cancer Gene Therapy
Data from Shanghai Jiao Tong University, Department of Gastroenterology advance knowledge in cancer gene therapy - Cancer Gene Therapy
Data on cancer gene therapy detailed by researchers at National Institutes of Health - Cancer Gene Therapy
Reports on cancer gene therapy findings from Washington University provide new insights - Cancer Gene Therapy
Research conducted at Nanjing Medical University has provided new information about cancer gene therapy - Cancer Gene Therapy
Research data from Korea Institute of Radiological and Medical Science update understanding of cancer gene therapy - Cancer Gene Therapy
Researchers from Lombardi Comprehensive Cancer Center, Department of Radiation Medicine detail findings in cancer gene therapy - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
